RIGL vs. GTHX, LXRX, AGEN, XOMA, VNDA, EBS, CDXS, ACHV, RGLS, and SGMO
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include G1 Therapeutics (GTHX), Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Codexis (CDXS), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector.
G1 Therapeutics (NASDAQ:GTHX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Rigel Pharmaceuticals has a net margin of -16.45% compared to Rigel Pharmaceuticals' net margin of -36.40%. G1 Therapeutics' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
G1 Therapeutics presently has a consensus target price of $8.67, indicating a potential upside of 162.63%. Rigel Pharmaceuticals has a consensus target price of $5.81, indicating a potential upside of 494.45%. Given G1 Therapeutics' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than G1 Therapeutics.
Rigel Pharmaceuticals has higher revenue and earnings than G1 Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, G1 Therapeutics had 11 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for G1 Therapeutics and 2 mentions for Rigel Pharmaceuticals. G1 Therapeutics' average media sentiment score of 1.16 beat Rigel Pharmaceuticals' score of 0.74 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
24.2% of G1 Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.1% of G1 Therapeutics shares are held by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Rigel Pharmaceuticals received 141 more outperform votes than G1 Therapeutics when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 66.10% of users gave G1 Therapeutics an outperform vote.
G1 Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats G1 Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
